Page 419 - Binder2

• Work with the immune system rather than subduing
it.
• Are designed for tolerization, not suppression.
• Offer fewer doses, fewer side effects, and more
sustained benefit.

Plant-based, orally delivered biologics—especially those
targeting mucosal immunity—hold the potential to
reprogram, not just suppress. To settle in, not just cycle
through.

The ethical mandate here is clear:

Design drugs that outlast symptoms—and outlive
patents.

Durability isn’t just about pharmacokinetics.
It’s about respecting the patient’s body and journey.

2. Ethically Accessible: Built for the Many, Not
the Few

Access remains the defining failure of modern biologics.

• In the United States, patients are often locked out by
high deductibles, insurance denials, and tiered
formularies.
• In low- and middle-income countries, many
biologics never arrive at all.
• Even in well-resourced systems, delays, exclusions,
and dropouts are common.

These barriers are not accidental. They are baked into the
architecture of delivery—cold-chain dependence, clinical

417